


#9

1653



Practitioner's Docket No. 0002.12

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

MAY 01 2001

TECH CENTER 1600/2900

In re application of: Patton, John S.

Application No.: 09/577,264

Group No.: 1653

Filed: May 22, 2000

Examiner: Unassigned

For: PULMONARY DELIVERY OF ACTIVE FRAGMENTS OF PARATHYROID HORMONE

Assistant Commissioner for Patents
Washington, D.C. 20231

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
WITHIN THREE MONTHS OF FILING OR
BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. section 1.97(b))

IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. section 1.97(b).

Date: April 23, 2001

Susan T. Evans
Signature of Practitioner

Reg. No.: 38,443
Tel. No.: 650-631-3100
Customer No.: 21968

Susan T. Evans
Inhale Therapeutic Systems, Inc.
150 Industrial Road
San Carlos, CA 94070

CERTIFICATE OF MAILING/TRANSMISSION (37 C.F.R. section 1.8(a))

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

FACSIMILE

☒ deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

☐ transmitted by facsimile to the Patent and Trademark Office.

Date: April 23, 2001

Karen J. Moir Karen J. Moir
Signature


Date: April 23, 2001
(type or print name of person certifying)

RECEIVED

MAY 01 2001

TECH CENTER 1600/2900

PATENT



Practitioner's Docket No. 0002.12

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Patton, John S.

Application No.: 09/577,264

Group No.: 1654

Filed: May 22, 2000

Examiner: Unassigned

For: PULMONARY DELIVERY OF ACTIVE FRAGMENTS OF PARATHYROID HORMONE

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT UNDER
37 CFR §1.97 AND §1.98

The references cited on attached forms PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. In accordance with 37 CFR §1.98(d), copies of the references can be found in corresponding United States Patent Application No. 09/128,401, filed August 3, 1998, Attorney Docket No. 0002.11. It is respectfully requested that the cited information be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent therefrom.

Applicant authorizes the Commissioner to charge the fee of \$240.00 to Deposit Account No. 500348.

Date:

April 20, 2001

Reg. No.: 38,443
Tel. No.: 650-631-3100
Customer No.: 21968

Signature of Practitioner

Susan T. Evans
Inhale Therapeutic Systems, Inc.
150 Industrial Road
San Carlos, CA 94070

Substitute for form 1449A/PTO

(use as many sheets as necessary)

Sheet 1 of 1

Application Number	09/577,264
Filing Date	05/22/2000
First Named Inventor	John S. Pat
Group Art Unit	1654
Examiner Name	Unassigned
Attorney Docket Number	0002.12

~~MAY 01~~ 2001

~~TECH CENTER~~ 1600/2900

[illegible][illegible]

Date	
Considered	

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

+

Please type a plus sign (+) inside this box ☐

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	09/577,264
Filing Date	05/22/2000
First Named Inventor	John S. Patton
Group Art Unit	1654
Examiner Name	Unassigned
Attorney Docket Number	0002.12

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
		Neer et al. (1987) Osteoporosis 53:829-835
		Hesch et al. (1988) Calcif. Tissue Int. 42:341-344
		Habener et al. (1971) Proc. Natl. Acad. Sci. USA 68:2986-2991
		Patton et al. (1992) Adv. Drug Delivery Reviews 8:179-196
		Harms et al. (1987) Int. Symp. On Osteoporosis, Aalborg, Abstr. 232:723-724
		Patton (1994) J. Controlled Release 28: 79-85
		Abstract of Japanese Patent, Document Number JP 02 000111, Date 01/05/90
		Patton (1998) Modern Drug Discovery, 19-28

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.